LPL Receptor
LPL receptor (lysophospholipid receptor) is a group of receptors that belong to GPCRs and are important for lipid signaling.
Products for LPL Receptor
- Cat.No. Product Name Information
-
GC42011
1-Oleoyl Lysophosphatidic Acid
A potent LPA receptor agonist
- GC39678 4-Deoxypyridoxine 5'-phosphate A vitamin B6 analog and an inhibitor of S1P lyase
- GC15908 AM-095 free base A selective LPA1 receptor antagonist
- GC15220 AM095 A selective LPA1 receptor antagonist
- GC13476 AM966 A potent and selective LPA1 receptor antagonist
- GC19031 Amiselimod hydrochloride Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
- GC31904 AS2717638 AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 38 nM for hLPA5.
- GC31870 ASP-4058 ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
- GC62851 ASP-4058 hydrochloride ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
- GC35409 ASP6432 ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC50s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively.
- GC17201 BAF312 (Siponimod) BAF312 (Siponimod) (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator.
- GC19078 BMS-986020 BMS-986020 is an LPA1 antagonist.
- GC38470 BMS-986020 sodium BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist.
- GC63895 BMS-986278 BMS-986278 is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM.
- GC19100 Cenerimod Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.
- GC18348 Ceralifimod Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively).
- GC10728 CYM 50260 S1P4 agonist
- GC15903 CYM 50308 S1P4 agonist
- GC16946 CYM 5541 sphingosine-1-phosphate receptor 3 (S1P3) allosteric agonist
- GC63345 CYM50358 CYM50358 is a potent and selective S1PR4 antagonist, with an IC50 of 25 nM.
- GC19146 Etrasimod Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells.
- GC43666 Fingolimod Fingolimod is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb I.
- GC14807 Fingolimod(FTY720) Fingolimod (FTY720) HCl (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator.
- GC68424 Fingolimod-d4 hydrochloride
- GC31736 FTY720 (S)-Phosphate ((S)-FTY720P) FTY720 (S)-Phosphate ((S)-FTY720P) is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
- GC62990 GLPG2938 GLPG2938 is a potent and selective S1P2 antagonist.
- GC31863 GSK2018682 An S1P1 and S1P5 receptor agonist
- GC38082 JTE-013 A selective S1P2 receptor antagonist
- GC11374 Ki16425 LPA receptor antagonist
- GC31958 LPA1 antagonist 1 LPA1 antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC50 of 25 nM.
- GC12655 LPA2 antagonist 1 selective inhibitor of LPA2 activity
- GC38923 LPA2 antagonist 2 LPA2 antagonist 2 (H2L 5226501) is a selective LPA2 antagonist with an IC50 of 28.3 nM and a Ki of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA3 (IC50 of 13.85 μM).
- GC62327 Mocravimod hydrochloride Mocravimod hydrochloride (KRP-203), an immunosuppressant, is a potent and orally active S1PR1 (sphingosine 1-phosphate receptor type 1) agonist.
- GC65579 ONO-0300302 ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM.
-
GC69624
ONO-0740556
ONO-0740556 is an effective Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC50 value of 0.26 nM.
- GC12362 ONO-7300243 LPA1 antagonist
- GC63128 ONO-9780307 ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC50 value of 2.7 nM.
- GC14360 Ozanimod (RPC1063) Ozanimod (RPC1063) (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5).
-
GC69645
Ozanimod hydrochloride
Ozanimod (RPC-1063) hydrochloride is a sphingosine 1-phosphate (S1P) receptor modulator that selectively and with high affinity binds to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has regulatory effects on hS1P1 and hS1P5 receptors, with EC50 values of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for research on relapsing multiple sclerosis (MS).
- GC50253 PF 543 hydrochloride Potent and selective SphK1 inhibitor
- GC36884 PF429242 dihydrochloride A site-1 protease inhibitor
- GC16660 Ponesimod sphingosine-1-phosphate receptor 1 (S1P1) modulator
- GC34752 Radioprotectin-1 Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA2), with an EC50 value of 25 nM for murine LPA2 subtype.
- GC65324 RP101988 RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.
- GC19316 S1p receptor agonist 1 S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.
- GC32006 S1PR1-MO-1 S1PR-MO-1 is the modulator of sphingosine-1-phosphate receptor, used for research of hyperproliferative, inflammatory diseases.
-
GC31785
SAR-100842
SAR-100842 is a potent, selective oral antagonist of the LPAR1, for diffuse cutaneous systemic sclerosis .
- GC65910 SAR247799 SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome.
- GC18116 SEW 2871 sphingosine-1-phosphate 1 (S1P1) receptor agonist
- GC66459 SLF1081851 SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system.
-
GC69926
Sonepcizumab
Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P. It has potential for use in the research of metastatic renal cell carcinoma (mRCC).
- GC14532 TC-G 1006 S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.
- GC13720 TY 52156 sphingosine-1-phosphate receptor 3 (SIP3) antagonist
- GC64434 Vibozilimod Vibozilimod (SCD-044, example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1).
-
GC15694
VPC 23019
S1P1/S1P3 receptor antagonist
-
GC16621
W146
sphingosine-1-phosphate receptor S1P1 antagonist
- GC63414 Zectivimod